Enzolytics Inc (ENZC)

[falon]

Although we all want to know what the heck is going on with ENZC and why they have been so silent on where they stand on results of on-going operations, we do know progress have been made albeit a bit or should say quite a bit behind schedule.

The biggest mystery is who are ALL the other players.

ENZC has shared over the past couple of years their progress and intentions as evident in press releases.

They have been limited in what they can release on certain information when NDAs were set up.

https://www.theglobeandmail.com/investing/markets/stocks/ENZC/pressreleases/

The NDAs suck do to lack of information however because of them we are likely to make a very profitable return on our investment.

To accelerate and fully execute the successful production of the multiple monoclonal antibodies, the subject of the Company's intellectual property (specifically the numerous monoclonal antibodies (mAbs) targeting both human and animal viruses), the Company continuously engages with numerous entities to accelerate its progress toward production, testing, and delivery of successful therapeutics. Entities with whom the Company is working include other Biotech Companies having:

? Technology and processes for accelerating the production of monoclonal antibodies that target critical virus
sites identified by the Company using its A.I. platform. The Company has identified critical conserved target
sites on 20 viruses, including human and animal viruses, and is engaging with biotech companies having
expertise in accelerating the production of such antibodies.

? Related, synergistic or complimentary therapeutics and business structure for the purpose of potential
combination with other biotech entities.

? Expertise in providing specialized peptides having precise amino acid sequences corresponding to the precise
target sites on both the Coronavirus and HIV viruses which are then used in the Company’s Texas lab against
which mAbs are being produced. This strategy accelerates the production of the mAbs for further development.

? Specialized cell sorting technology that is complementary to the process used in the Company’s lab to
accelerate production of mAbs for advancing production.

? Expertise in hybridoma production techniques for producing mAbs using hybridoma methodologies
complementary to the process used in the Company's lab.

? Animal trials centers, both in the U.S. and abroad, for the preparation of animal trials.

? Promotional entities with specialized expertise in targeting large funding sources for the purpose of raising the
substantial funds needed for the production of the recombinant mAbs necessary for future trials and for
conducting animal trials.

As to each of these entities and those with whom the Company currently works on an ongoing basis, the Company has
entered into NDAs (Nondisclosure Agreements) necessary to preserve and protect the Company plans and intellectual
property being discussed and exchanged between the parties. These contractual restrictions are critical for the Company
and its partners. Maintenance of strict confidentiality is essential to preserving intellectual property rights (patent rights)
which are now being sought and will be sought in the future. Premature disclosure of information can bar the right to
seek patent protection at a later date. The Company is not able to share specific details regarding arrangements
regarding these NDAs.

The term of these NDAs is not time limited. The term extends until the later of five (5) years from the Effective Date or
"until such time as the proprietary information is publicly known and made generally available". This provision is
necessary because under Patent Laws an issued patent may be invalidated where the patent is filed subsequent to
public disclosure of the invention claimed. In view of this limitation, the Company makes no public disclosure of
information subject to NDAs and inventions covered by them.
Additionally, certain technical information shared with companies with whom the Company has entered into an NDA may
not be included in a patent application, but rather the subject technical information is maintained as Company confidential
("secret") indefinitely. Also, in these Agreements, the parties generally agree not to reveal the names of the contracting
parties for a specified period.

The Company is very confident in its Artificial Intelligence empowered Intellectual Property Portfolio. It has allowed the
Company to claim exclusive rights on an international stage covering critical target sites on numerous human and
animal viruses. This places the Company on an equal level with the largest biotech companies in that the Company is
the first to identify and patent critical sites on many human and animal viruses. This same technology and strategy are
being implemented by the Company on new viruses, human or animal. The Company identified the conserved sites on
the Monkeypox Virus even before the World Health Organization declared it a global health emergency last week.
The Company believes that its extensive patent portfolio will provide a return on investment through partnering or
licensing technology covered by multiple international patents.

http://www.otcmarkets.com/otcapi/company/financial-report/346487/content